COVID-19 vaccine reaches phase-2 trials in China
Share - WeChat

BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- Blood donation rate rises, shortages remain
- Typhoon Wutip spurs emergency response
- China's BMI tech reaches new heights
- Gambian farmer pays tribute to 'father of hybrid rice'
- China enhances coastal ecosystem protection and restoration
- Jiangsu presents innovation-driven growth and economic leadership